会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明公开
    • 제지공정용 슬라임콘트롤제 조성물 및 이를 이용한슬라임콘트롤 방법
    • 用于造纸工艺的SLIME控制剂组合物和使用它的糊状物的控制方法
    • KR1020010063993A
    • 2001-07-09
    • KR1019990062106
    • 1999-12-24
    • 에스케이 주식회사
    • 주홍신송원성
    • D21H21/36
    • D21H21/04
    • PURPOSE: Provided are a slime controlling agent composition for paper-making process which is characterized by strong antibacterial force, far-reaching antibacterial spectrum, excellent fast-acting property, excellent persistence, an effect of lowering an appearing frequency of resistant bacteria, a little virulence and few bubble, and being useful for various field of industry, and a controlling method of slime using the same. CONSTITUTION: The slime controlling agent composition is obtained by mixing polyhexa methylene guanidine phosphate(formula 1) with 2-bromo-2-nitro-1,3-propane diol(formula 2) in a weight ratio of 1-16. In the formula 1, m is an integer of 4-7, and n is an integer of 1-14. In case of a liquid-phase composition, reactivating ingredients of the polyhexa methylene guanidine phosphate and the 2-bromo-2-nitro-1,3-propane diol are 25wt.% respectively. The controlling method of slime is characterized by putting periodically 20-1000ppm of the composition to a pipe and a chest of the paper-making process per 8-24hours. In case of powder, 20-200ppm of the composition is put. In case of aqueous solution, 50-1000ppm of the composition is put.
    • 目的:提供造纸工艺的粘液控制剂组合物,其特征在于抗菌力强,抗菌谱远,抗张力性能优异,持久性优异,抗菌细菌出现频率降低的作用 毒性少,泡沫少,适用于各种工业领域,采用相同的粘液控制方法。 构成:通过将聚六亚甲基磷酸胍(式1)与重量比为1-16的2-溴-2-硝基-1,3-丙二醇(式2)混合来获得粘液控制剂组合物。 在式1中,m为4-7的整数,n为1-14的整数。 在液相组合物的情况下,重复使用聚六亚甲基磷酸胍和2-溴-2-硝基-1,3-丙二醇的成分分别为25重量%。 粘土的控制方法的特点是每8-24小时定期将20-1000ppm的组合物放在造纸工艺的管道和胸部。 在粉末的情况下,放置20-200ppm的组成。 在水溶液的情况下,放入组合物的50-1000ppm。
    • 9. 发明公开
    • 항암제 내성을 갖는 뉴클레오포스민 유전자, 및 이의이용방법
    • 具有抗癌药物耐受性的核苷酸基因及其用途
    • KR1020040008458A
    • 2004-01-31
    • KR1020020042096
    • 2002-07-18
    • 에스케이 주식회사
    • 조재훈조수진주홍신유영도
    • C12N15/12
    • C07K14/47G01N33/502G01N33/5044G01N2800/44
    • PURPOSE: A nucleophosmin gene having anticancer agent tolerance and the use thereof are provided. The nucleophosmin gene is used for the diagnosis of anticancer agent tolerance and for the prescription of an anticancer agent optimized for a patient. CONSTITUTION: A nucleophosmin gene having anticancer agent tolerance has the nucleotide sequence of SEQ ID NO: 1. A method for screening a drug for overcoming the anticancer agent tolerance comprises the steps of: inserting the nucleophosmin gene of SEQ ID NO: 1 into a cancer cell and expressing it within the cancer cell; administrating an anticancer agent or an anticancer agent tolerance overcoming drug to the cancer cell; and analyzing proliferation of the cancer cell, wherein the cancer cell is a lung cancer cell or a stomach cancer cell; and the anticancer agent is selected from cisplatin, carboplatin, taxol, adriamycin, fluorouracil(5-FU), and etoposide(VP-16). A method for diagnosis of anticancer agent tolerance comprises analysis of expression of the nucleophosmin gene within the cancer cell.
    • 目的:提供具有抗癌剂耐受性的核磷酸基因及其用途。 核磷酸基因用于诊断抗癌药物耐受性和用于为患者优化的抗癌剂的处方。 构成:具有抗癌剂耐受性的核磷酸基因具有SEQ ID NO:1的核苷酸序列。用于筛选药物以克服抗癌剂耐受性的方法包括以下步骤:将SEQ ID NO:1的核磷酸基因插入癌症 并在癌细胞内表达; 向癌细胞施用克服药物的抗癌剂或抗癌剂耐受性; 并分析癌细胞的增殖,其中所述癌细胞是肺癌细胞或胃癌细胞; 抗癌剂选自顺铂,卡铂,紫杉醇,阿霉素,氟尿嘧啶(5-FU)和依托泊苷(VP-16)。 用于诊断抗癌药物耐受性的方法包括分析癌细胞内核磷酸基因的表达。